Amlodipine/Valsartan and Lithium Interaction

Understanding the Amlodipine/Valsartan and Lithium Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Amlodipine/Valsartan belongs to the CCB / ARB Combination class and Lithium belongs to the Mood Stabilizer class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Valsartan can make it harder for your kidneys to clear lithium from your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Amlodipine/Valsartan has 14 total documented interactions on file in this dataset, and Lithium has 90. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor your lithium levels closely to prevent toxicity while you are taking these drugs together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Amlodipine/Valsartan or Lithium based on a web page, speak with your prescriber or pharmacist before making any change.